CST3 and prostate carcinoma: It is worth noting that they also found significantly elevated cystatin C levels in prostate cancer patients treated with zoledronic acid, implying that cystatin C may be a potential marker for monitoring treatment response after receiving bisphosphonate-type drugs in prostate cancer patients who develop bone destruction.